Sangamo: SB-525 Therapy Receives Orphan Medicinal Product Designation From EMA – Nasdaq
KL Daily |
Sangamo: SB-525 Therapy Receives Orphan Medicinal Product Designation From EMA
Nasdaq In May 2017, Sangamo and Pfizer entered into a global collaboration and license agreement to develop and commercialize gene therapy programs for hemophilia A, including SB-525. Under the agreement, Pfizer will be responsible for any subsequent … Sangamo Biosciences (SGMO) & Pfizer (PFE) Granted Orphan Medicinal Product Designation from European … EMA Grants Orphan Medicinal Product Designation to SB-525 for Hemophilia A |
